Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03783078 |
| Title | Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Merck Sharp & Dohme Corp. |
| Indications | |
| Therapies | |
| Age Groups: | adult | child | senior |
| Covered Countries | USA | SWE | NZL | ITA | FRA | ESP | CAN | AUS |